In the phase III CASPIAN trial, patients with untreated SCLC were assigned to received durvalumab, an IgG1 kappa anti-PD-L1 monoclonal human antibody, plus platinum-etoposide or durvalumab plus tremelimumab (an IgG2 anti-CTLA-4 fully human monoclonal antibody) plus platinum-etoposide followed by durvalumab as maintenance, until disease progression or unacceptable toxicity, or chemotherapy alone [23]. This evidence concerns the gene CD274 and small cell lung carcinoma.